Blepharoptosis surgery in patients with myasthenia gravis

被引:20
|
作者
Litwin, Andre S. [1 ]
Patel, Bhupendra [2 ]
McNab, Alan A. [3 ]
McCann, John D. [4 ]
Leatherbarrow, Brian [5 ]
Malhotra, Raman [1 ]
机构
[1] Queen Victoria Hosp NHS Trust, Corneoplast Unit, E Grinstead RH19 3DZ, W Sussex, England
[2] Univ Utah, Moran Eye Ctr, Div Facial & Orbital Cosmet & Reconstruct Surg, Salt Lake City, UT USA
[3] Royal Victorian Eye & Ear Hosp, Orbital Plast & Lacrimal Clin, Melbourne, Vic 3002, Australia
[4] Ctr Facial Appearances, Salt Lake City, UT USA
[5] Manchester Royal Eye Hosp, Manchester M13 9WH, Lancs, England
关键词
SURGICAL-CORRECTION; PTOSIS; DISEASE;
D O I
10.1136/bjophthalmol-2014-306335
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background/aims To review our approach of cautious surgical correction of blepharoptosis in patients with myasthenia gravis (MG) to minimise risk of exposure complications. Methods Retrospective case note review of 30 patients with symptomatic eyelid concerns despite appropriate medical treatment, who underwent eyelid surgery. The mean age at diagnosis was 47 years. 13/30 patients had systemic MG, 14/30 ocular MG and 3/30 congenital MG. The main outcome measures were improvement in eyelid height and/or position, duration of a successful postoperative result, need for further surgical intervention, and intraoperative or postoperative complications. Results 38 blepharoptosis procedures were performed on 23 patients. Mean age at time of surgery was 62 years, with an average follow-up of 29 months. 10 patients (16 eyelids) underwent anterior approach levator advancement, 4 patients (5 eyelids) posterior approach surgery and 8 patients (15 eyelids) brow suspension. One patient (2 eyelids) had tarsal switch surgery. An average improvement in eyelid height of 1.9 mm was achieved. Postoperative symptoms or signs of exposure keratopathy occurred in 17% of patients. This necessitated lid lowering in one eyelid of one patient. During follow-up, 37% of eyelids required further surgical intervention to improve the upper eyelid height, after an average of 19 months (range 0.5-49 months). Conclusions Over a third of patients in our series required repeat surgery, which would be expected when the initial aim was to under-correct this group. In contrast to previous commentaries, the amount of eyelid excursion was not the main factor used to guide the surgical approach.
引用
收藏
页码:899 / 902
页数:4
相关论文
共 50 条
  • [31] Myasthenia gravis and risks for comorbidity
    Gilhus, N. E.
    Nacu, A.
    Andersen, J. B.
    Owe, J. F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 (01) : 17 - 23
  • [32] Update on Ocular Myasthenia Gravis
    Smith, Stacy V.
    Lee, Andrew G.
    NEUROLOGIC CLINICS, 2017, 35 (01) : 115 - +
  • [33] Update on Ocular Myasthenia Gravis
    O'Hare, Meabh
    Doughty, Christopher
    SEMINARS IN NEUROLOGY, 2019, 39 (06) : 749 - 760
  • [34] Autoimmune myasthenia gravis in a ferret
    Couturier, Jerome
    Huynh, Minh
    Boussarie, Didier
    Cauzinille, Laurent
    Shelton, G. Diane
    JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2009, 235 (12): : 1462 - 1466
  • [35] Pediatric Ocular Myasthenia Gravis
    Kristen Fisher
    Veeral Shah
    Current Treatment Options in Neurology, 2019, 21
  • [36] Ocular aspects of myasthenia gravis
    Barton, JJS
    Fouladvand, M
    SEMINARS IN NEUROLOGY, 2000, 20 (01) : 7 - 20
  • [37] The thymus, thymoma and myasthenia gravis
    Fujii, Yoshitaka
    SURGERY TODAY, 2013, 43 (05) : 461 - 466
  • [38] Inflammation and autoimmune myasthenia gravis
    Huda, Ruksana
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [39] Myasthenia gravis: an icy diagnosis
    Garcia-Grimshaw, Miguel
    Posadas-Pinto, Diego
    POSTGRADUATE MEDICAL JOURNAL, 2019, 95 (1128) : 567 - 567
  • [40] Biomarker development for myasthenia gravis
    Kaminski, Henry J.
    Kusner, Linda L.
    Wolfe, Gil I.
    Aban, Inmaculada
    Minisman, Greg
    Conwit, Robin
    Cutter, Gary
    MYASTHENIA GRAVIS AND RELATED DISORDERS II, 2012, 1275 : 101 - 106